Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Guy Gordon who wrote (2156)	3/26/1999 3:23:00 PM
From: dennis michael patterson	Read Replies (1) \| Respond to of 10280

So, what explains the action now?

To: Guy Gordon who wrote (2156)	3/26/1999 3:41:00 PM
From: Don Miller	Respond to of 10280

More Press, Executive Business Briefing FRIDAY, MARCH 26, 1999 1:58 PM EST - United Press Intl. Here's a look at the hour's top business stories: Sepracor has announced it won Food and Drug Administration approval to market a new asthma drug. The Massachusetts-based company says the FDA approved Xopenex inhalation solution for use with a nebulizer in the treatment of bronchospasm, following clinical trials. The tests showed the drug was effective for up to eight hours for each dose.